{"entity":{"id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 3 trial of Nadofaragene firadenovec in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.","summary":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06510374 by Ferring Pharmaceuticals, with 454 participants planned, started 2024-10-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: Nadofaragene Firadenovec.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06510374","url":"https://clinicaltrials.gov/study/NCT06510374"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["nadofaragene-firadenovec"],"companies":["ferring"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06510374","phase":"3","setting":"A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","sponsor":"Ferring Pharmaceuticals","enrolled":454,"outcomes":[]},"route":"/trials/nct06510374/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/"}],"company":[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/"}]}}